Ranbaxy To Seek Indian Strategic Alliance With Orchid
This article was originally published in PharmAsia News
Executive Summary
Instead of a rumored hostile takeover, Ranbaxy Group appears close to a strategic alliance with Orchid Chemicals & Pharmaceuticals. Solrex Pharmaceuticals, believed to be a Ranbaxy-promoted company, is not expected to increase its recently acquired 14.7 percent share in Orchid, which would have put its investment at the 15 percent threshold requiring it to offer to buy an additional 20 percent of shares. A Ranbaxy-Orchid strategic relationship is seen as beneficial to both since Orchid makes active pharmaceutical ingredients and Ranbaxy already has a strong position in U.S. markets. Neither firm would confirm the plan. (Click here for more
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.